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Background: To test if oral D-methionine (D-met) reduced mucositis during 
chemoradiotherapy.   
  
Methods: Placebo controlled double-blind randomized Phase 2 trial of D-met (100 
mg/kg po BID) testing the rate of severe (grade 3-4) mucositis.  
  
Results: Sixty patients were randomized.  Grade 2+ oral pain was higher with placebo 
(79% vs. 45%, p=0.0165) while grade 2+ body odor was greater with D-met (3% vs. 
41%, p=0.0015). Mucositis was decreased with D-met by physician (WHO, p=0.007, 
RTOG, p=0.009) and patient functional scales (RTOG, p=0.0023).  The primary end-
point of grade 3-4 mucositis on the composite scale demonstrated a decrease with D-met 
(48% vs. 24%, p=0.058) which was borderline in significance. A planned secondary 
analysis of a semi-quantitative scoring system noted decreased oral ulceration (2.2 vs. 
1.5, p=0.023) and erythema (1.6 vs. 1.1, p=0.048) with D-met.  
 
Conclusions: Although not meeting the primary end-point, results of multiple 
assessments suggest that D-met decreased mucositis.  
 
147/150 words 
Page 4 of 43
John Wiley & Sons, Inc.
Head & Neck









t Phase 2 Study of D-Methionine to Prevent Mucositis  
5 
 
Statement of Translational Relevance 
 
Mucositis is a common dose-limiting side-effect of radiation therapy in head and neck 
cancer patients.  To date no clear treatment that mitigates this toxicity for this patient 
population has been routinely adopted.  Previously it was demonstrated that D-
methionine (D-met) could protect non-transformed human cells in culture from radiation 
induced cell death while not similarly protecting tumors cells.   In addition, a phase I trial 
demonstrated the safety and bioavailability of oral D-met with a suggestion of decreased 
mucositis compared to historical controls.   Here we demonstrate in a multi-institutional 
randomized placebo controlled phase 2 trial that D-met had no significant increased 
toxicity but was associated with decreased oral mouth pain and mucositis for patients 
treated with concurrent RT and cisplatin for SCCHN.  
 
Summary : 120 words. 
 
Manuscript: 4854 words 
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In the U.S., approximately 49,670 patients in 2017 will be newly diagnosed with cancers 
of the head and neck, and approximately 9,700 will die from this disease(1). The 
combination of chemotherapy and radiotherapy (ChemoRT) is commonly utilized in 
patients with squamous cell cancers of the head and neck (SCCHN). Oral mucositis (OM) 
is a dose-limiting side-effect of chemoRT which is characterized by mucosal erythema 
and ulceration often with secondary bacterial or fungal infections with severe OM 
occurring in 40-80% of patients(2).  A wide range of different therapies have been 
evaluated for OM including: antimicrobials(3,4), cytokines(5-8), keratinocyte growth 
factor(9), anti-inflammatories(10-12), coating rinses(13), honey(14-17), glutamine(18), 
cryotherapy(19), and laser treatment(20).  The microbial make-up of the oral cavity has 
also been noted to influence the development of mucostiis with the flora within the oral 
cavity or the cytokine response prognostic for OM(21,22). 
D-methionine (D-met) is the dextro isomer of the essential amino acid, L-methionine; 
while MRX-1024 is a high-concentration (200 mg/ml) bio-available suspension 
formulation of D-met (Molecular Therapeutics Inc, Ann Arbor, MI). D-methionine is a 
natural micronutrient with both the D- and L-isomers present in high-concentrations in a 
normal diet. Due to minimal human catabolism D-met results in higher plasma levels 
than L-met with >60% of D-met excreted without conversion (23-26).  Clinically, L-met 
has been available for decades for treatment of dermatitis (200-400 mg po TID-QID) 
while the racemic mixture has been used to treat acetaminophen overdose (10 g po over 
12 hr).(27-31)  The most common side-effect of oral methionine is nausea.   
D-methionine was previously demonstrated in animal models to protect against oxidative 
stress associated ototoxicity and nephrotoxicity from cisplatin, aminoglycosides, or noise 
related injury.(32,33)  D-methionine also protected non-transformed human cells 
(fibroblasts, keratinocytes, and endothelial cells) from RT associated cell death with a 
protective factor in clonogenic assays of 1.2-1.6. Notably,  radiation protection was not 
observed in transformed human tumor cell lines in vitro or in vivo.(34)  Fractionated 
irradiation of mouse oral mucosa for 5 days resulted in higher peak mucositis in control 
animals compared to animals pre-treated with D-met with a dose dependent increase in 
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radiation protection from  200, 300, and 500 mg/kg yielding protective factors of 1.6, 2.1, 
and 2.6, respectively (p<0.0003).(34) More recently others demonstrated protection from 
radiation injury with D-met in mouse and zebra fish models.(35,36) 
The long clinical use of D-met plus the pre-clinical data showing protection from 
mucosal injury led to a previously reported Phase I clinical trial where 25 patients with 
SCCHN were treated with fractioned RT (with 78% also receiving cisplatin)(37).  
Pharmacokinetic analysis revealed that when administered orally at 100 mg/kg, peak and 
area under the curve (AUC) levels of D-met were comparable to the levels previously 
associated with mucosal protection in rodents.  There was a modest increase in 
nausea/vomiting following D-met with 5 patients withdrawing from the study due to 
nausea and emesis, but only 1 (1/25, 4%) incidence of dose limiting toxicity (grade 3 
emesis). Only one in 18 patients (6%) had grade 3 mucositis with no grade 4 mucositis.  
We report here a randomized controlled Phase 2 trial of orally administered D-met along 
with concurrent weekly cisplatin and radiotherapy for SCCHN involving the oral cavity 
and/or oral pharynx.    
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Materials and Methods 
Trial Design 
After local IRB approval a double blind placebo controlled clinical trial was performed at 
4 institutions in India (See Figure 1, Supplemental Table 1).  Patients were to have newly 
diagnosed cancers of the head and neck with a plan to receive concurrent cisplatin and 
radiotherapy (minimum 60 Gy in conventional fractions) to at least 50% of the oral 
cavity, oral pharynx, or both. Following informed consent and enrollment patients were 
randomly assigned to one of two treatments (D-met or placebo) in a 1:1 ratio using a 
computer-generated algorithm stratified by center using a fixed block size.   
 
Radiation Therapy 
Treatment was with either a 
60
Co teletherapy unit or linear accelerator (≥4MeV) using 
either 2D or 3D based CT-planning. No intensity modulated radiotherapy was used. 
Portal margins were shaped using cerrobend blocks or a multileaf collimator. 
Compensators or wedges were used to assure dose homogeneity that was ± 5% of the 
midplane central axis dose. Opposed photon portals were used while wedge pair 
techniques that spare mucosa on one side were excluded except when used to boost the 
primary tumor after delivery of a minimum dose of 60 Gy. The administration of 
radiation was such that the oropharyngeal mucosa was planned to receive a central axis 
midplane dose of 60-70 Gy over 6-7 weeks, 1.8 to 2.0 Gy once a day.  
 
Cisplatin  
All patients entering the study were medically appropriate to receive cisplatin which was 
administered intravenously (50 mg per week) after the patient received the RT scheduled 
for that day.  This was on average 28 mg/m
2
 and reflected the common practice. Patients 
were hydrated with normal saline administered intravenously (500-1500 ml over 3-4 
hours). All patients receiving cisplatin were to receive an antiemetic regimen sufficient to 
ameliorate this expected adverse event with 4-16 mg of ondansetron plus 5-20 mg of 
dexamethasone recommended; variation was allowed by institution.   
 
 
Page 8 of 43
John Wiley & Sons, Inc.
Head & Neck













The active pharmaceutical ingredient in MRX-1024, manufactured by stereo-specific 
chemical synthesis according to cGMP guidelines, is D-methionine (CAS Registry 
Number 348-67-4, manufactured by Natco Pharma Ltd, Banjara Hills, Hyderabad, India).  
Supplies of D-met or placebo were provided in identical amber bottles with the same 
labels, buffered solution, and flavoring.  Patients, physicians, or study personnel 
responsible for preparing individual doses or for evaluating patient outcomes were unable 
to distinguish D-met from placebo. 
 
D-methionine - Method of Administration 
D-met (200 mg/ml) or placebo were stored at controlled ambient room temperature. The 
amount to be administered was based upon the patient’s body weight in the preceding 
week at a dose of 100 mg/kg BID.   The suspension was measured out by study personnel 
and the patients ingested the drug in their presence.  No attempt to swish, swallow, or 
gargle the suspension was recommended or required. Patients were not allowed to self-
medicate. Based upon pre-clinical data the first dose was to be taken 30-60 minutes prior 
to RT and the second 30-60 minutes post-RT daily.(34) The drug was not taken on days 
when radiation was not delivered. Patients should not have consumed anything by mouth 
(other than water and scheduled medications) for one hour prior to receiving study drug.  
 
Study Assessments, Visit Schedule 
Potential study participants were screened versus the inclusion and exclusion eligibility 
criteria which are provided in Supplemental Table 1.  All patients had to have head and 
neck cancer with a plan to deliver concurrent cisplatin and radiotherapy. Eligible and 
consenting patients completed a baseline evaluation that included a physical examination 
with an oral examination, medical history, vital signs, blood collection for specified 
laboratory tests, and when appropriate a serum pregnancy test.   
 
Patients were seen according to the following schedule:  a screening visit (-21 to -1 day 
prior to treatment), baseline (before first dose of drug on Day 1), during treatment (at the 
end of the week for each of 6-7 planned weeks of ChemoRT with the last appointment 
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after the last dose of drug was taken), and then 30 days after the end of treatment.  
Patients had weekly complete blood count (CBC) and comprehensive metabolic panel. 
Toxicities were evaluated by CTCAE version 3.0 at each planned visit.  
Adverse events were documented at each study visit. Oral mucositis was assessed as 
indicted below. All patients who received at least one dose of study drug and one fraction 
of RT were considered evaluable and included for analysis. The last follow-up per 
protocol was 30 days post treatment with no extended follow-up planned 
 
Initially an analysis of patient reported outcomes with the FACT-H&N instrument was 
planned; however, due to a lack of validated instruments in several of the local dialects 
this aim was discontinued.    
 
Adverse Events (AE) 
Investigators, blinded to the assigned study medication being received by each patient 
evaluated each reported AE for the likelihood that the event was attributable to the study 
medication (D-met/placebo).  The Investigators judged AE as being Definitely, Probably, 
Possibly, Not Likely, or Unrelated to the study medication.   
 
Serious Adverse Events (SAE) were reported to the local IRBs and were defined as  an 
AE that met any of the following: 
• Death; 
• Life-threatening; 
• Persistent or significant disability and/or incapacity; 
• Required inpatient hospitalization; 
• Other medically significant event that may jeopardize the patient and may 






Page 10 of 43
John Wiley & Sons, Inc.
Head & Neck









t Phase 2 Study of D-Methionine to Prevent Mucositis  
11 
 
• The primary objective was to determine the efficacy of orally administered D-
met in reducing the percentage of patients who develop serious (Grade 3 or 4) 
oral mucositis.   
 
Planned secondary objectives included:  
• To determine if patients receiving D-met experience fewer complications 
normally associated with the development of oral mucositis compared to 
patients receiving placebo, specifically fewer hospitalizations for infection, 
less weight loss during treatment, less opioid analgesic consumption, and 
fewer days receiving parenteral nutrition; 
• To determine if patients receiving D-met were able to complete their 
radiation and chemotherapy treatment sooner than patients receiving 
placebo; 
• To determine if patients receiving D-met obtained a similar antitumor 
response to radiation and chemotherapy as patients receiving placebo.  
 
Oral Mucositis Assessments  
Study personnel at each site were trained in standardized mucosal evaluations prior to 
opening the study. At each visit (see Figure 1), study personnel examined the oral cavity 
and recorded results using each of four methods for assessing oral mucositis. These 
included the World Health Organization (WHO) grading scale for mucositis 
(Supplemental Table 2), The Radiation Therapy Oncology Group (RTOG) Oral 
Mucositis Grading System: Gross Physician Rating (Supplemental Table 3), the RTOG 
Functional Patient Rating (Supplemental Table 3), and the Objective Scoring System for 
Site Assessment (OSSFA, Supplemental Table 4)(38).  
 
Assessment of Tumor Response 
Each patient had a CT scan of the head and neck performed within 15 days prior to 
beginning treatment and again 30 days after receiving their last dose of radiotherapy.  
The CT scans were reviewed by an independent radiologist (B.P.) at the completion of 
the study who was blinded to treatment allocation.  The mass lesions from the baseline 
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and follow-up CT scans were recorded and their measurements used to stratify patients 
by RECIST criteria.   
  
Sample Size and Statistical Plan 
Patients with SCCHN receiving treatment with ChemoRT were anticipated to have 70% 
incidence of severe (Grade 3 or Grade 4) oral mucositis.  Based on the Phase 1 trial of 
MRX-1024 this was estimated at 10% in the experimental arm.  Using a power of 0.9 and 
a significance level of 0.01, required a total of 40 evaluable patients; 20 per arm.  
Historical data within India suggested that a higher number of patients should be enrolled 
to account for non-completing patients due to economic, social, cultural or other reasons.  
For this reason, a sample size of 60 patients, 30 patients per arm, was selected in order to 
achieve 40 evaluable. The study was powered for the primary but not for the secondary 
objectives.  
 
The statistical analysis plan, determined prior to unmasking of the randomization code, 
established the primary end-point as the proportion of patients experiencing Grade 3 or 
greater OM using a composite of the highest score noted during treatment using the 
WHO and the 2 RTOG scales.  Secondary analyses were planned per protocol while 
unplanned secondary analyses were performed as indicated in a post hoc manner.  
 
The protective effect of D-met was measured based upon cumulative mucositis and peak 
mucositis measurements using the area under the time mucositis curve (AUC) which was 
calculated using PK Functions for Microsoft Excel, a series of Add-in functions for Excel 
spreadsheets, designed and written by Joel I. Usansky, Atul Desai, and Diane Tang-Liu 
(Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, CA).  All other 
statistical analysis was performed with MedCalc Statistical Software version 17.2 
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2017).  All p-
values of <0.05 were considered statistically significant without correction for multiple 
comparisons. 
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The first patient was enrolled on July 29, 2005 and the last on March 17, 2006.   All 
patients have completed their participation on this protocol. Eligible and consenting 
patients were randomized 1:1 to receive either MRX-1024 (an oral suspension of D-
methionine) or a placebo.  Treatment with the combination of radiation, cisplatin, and D-
met/placebo continued until a total of 60-70 Gy of radiation was administered over 6 to 7 
weeks, or until the patient terminated treatment for any reason.  
 
Demographics 
There were no differences between treatment arms in any clinical or demographic criteria 
(Table 1).  All patients were of Indian ancestry with 76% male, median age of 51 years, a 
median KPS of 90, and >95% with squamous cell carcinoma (with 3 cases of poorly 
differentiated carcinoma) with involvement of the oral cavity (90%) and/or oropharynx 
(10%).  Forty-five percent of patients had stage group III/IV disease with 15.5% with 
positive lymph nodes. 
 
Treatment 
The treatment delivered is outlined in Table 2. Median number of radiation fractions 
delivered was 31 with no difference between arms with a median total dose 62 Gy in 1.8-
2.0 Gy fractions.  There was no difference in the type of radiation equipment utilized 
(Linac vs. 
60
Co, p>0.5). Patients on the placebo arm did take longer to complete all 
treatment (median 48 vs. 42 days, p=0.05).  On both arms 86% of patients received at 
least one dose of cisplatin with the median number of weekly cycles on each arm being 4.  
The median doses of study drug delivered was 62 which was slightly higher for placebo 
(64) as compared to control (60, p=0.096).     
 
Adverse Events, Patient Withdrawals, and Deviations. 
Overall 30 patients were randomized to each arm (n=60 total) with 29 patients on each 
arm initiating treatment. A similar proportion of patients did not complete treatment and 
follow-up on the D-met arm (8/29: 28%) as compared to the placebo arm (5/29: 17%) 
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(p=0.6). On the experimental arm 4/8 patients not completing treatment were for adverse 
events all 4 of which were from nausea and/or vomiting.  There was one case of grade 1, 
two of grade 2, and one of grade 3.  On the control arm one patient had neutropenic fever 
and sepsis and subsequently died on day 32 of study. This was not felt to be related to 
study drug (placebo). 
 
Adverse events by maximum intensity for those reported in >10% of all patients are listed 
in Table 3. All patients experienced at least one adverse event of grade 1 or greater.  The 
proportion of patient experiencing Grade 2+ AEs (27/29: 93% control vs. 28/29: 97% D-
met, p=0.7) or Grade 3+ AEs (12/29:41% control vs. 10/29:34% D-met, p=0.8) were also 
not different between treatment arms   There was greater nausea with D-met as compared 
to placebo (55% vs. 17%, p=0.005) but the majority (11/16) was  Grade 1.  There was no 
difference in Grade 2+ nausea between arms (17% vs. 10%, p=0.7). For grade 2 or 
greater AEs only pain in oral cavity (Grade 2+: 23/29 (79%) placebo vs. 13/29 (45%)  D-
met, p=0.0165) and body odor (Grade 2+: 1/29 (3%) placebo vs. 12/29 (41%) D-met, 
p=0.0015) were different between arms. There were no differences in adverse laboratory 
assessments (Supplemental Tables 5 and 6). 
 
Serious adverse events per protocol are provided (Supplemental Table 7) with all  SAEs 
deemed not related to study medication and no differences in the rate of SAEs per arm 
(Placebo:13, D-met:11, p>0.5). There were also no differences in significant protocol 
violations between arms (Supplemental Table 8).  One notable violation is that 11/29 
(38%) of D-met and 12/29 (41%) of placebo patients received 5-floururacil in addition to 
cisplatin during ChemoRT which was not part of the protocol treatment.  
 
Mucositis Evaluations  
Patients were evaluated by the treating team at the start of treatment, weekly during RT, 
and then post treatment day 30 (see Figure 1).  Three mucositis scales were evaluated: the 
WHO physicians scored scale (Figure 2A), the RTOG Gross Physician Rating (Figure 
2B), and the RTOG Functional Patient Rating (Figure 2C).  A composite scale was also 
utilized that was the highest score on each of the three scales (Figure 2D).  For both 
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physician scored scales (WHO and RTOG) there was a greater rate of mucositis (on a 0-4 
scale) with placebo as compared to D-met (p=0.007 WHO, p=0.0009 RTOG) as well as a 
higher rate of Grade 3-4 mucositis (41% vs. 17% WHO, p=0.045; 48% vs. 21% RTOG, 
p=0.0285). For the RTOG Functional Patient Rating there was a lower rate of mucositis 
overall with D-met (p=0.0023) but the difference in grade 3-4 mucositis favoring D-met 
was not statistically significant (41% vs. 24%, p=0.16).   
 
The primary end-point, pre-determined prior to analysis, was a reduction in the rate of 
grade 3-4 mucositis using the composite scale (Figure 2D).  This was twice as likely with 
placebo (14/29: 48%)  as compared to D-met (7/29: 24%), but this difference was not 
statistically significant (p=0.058). However, the overall mucositis score (0-4) was lower 
with the use of D-met (p=0.0018). On the composite scale 31% (9/29) of D-met patients 
had grade 0-1 mucositis while this was only 3% (1/29) on the placebo arm (p=0.008).  In 
addition, if grade 3 and 4 mucositis were considered separately (where there were 2 cases 
(7%) grade 4 on the control arm as compared to zero cases on the experimental arm) 
there was also a difference favoring D-met (p=0.033).  Finally one patient on the placebo 
arm died of sepsis after developing grade 4 mucositis (by the WHO and the RTOG 
patient scale with grade 3 mucositis by the RTOG physician scale) after 38 Gy in 2 Gy 
fractions and 4 weekly doses of cisplatin while there were no deaths on the experimental 
arm.   
 
For those who developed grade 3-4 mucositis using the composite scale (14 placebo and 
7 control) this occurred on average 24 (SD:13) days from starting treatment on the 
placebo arm and 30 (SD:8) days on the D-met arm (p>0.2). 
 
Secondary End-Points 
Planned Secondary End-Points 
An additional scoring system was also utilized per protocol where 9 areas in the mouth 
were assessed weekly for both ulceration and erythema (See Supplemental Table 4)(38). 
The instrument was scored as described with the data plotted in Figure 3A as the average 
peak scores summated from each of those 9 areas over time. For ulceration as a 
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continuous scale (0-3) the use of D-met was associated with a 0.7 point reduction in the 
average peak ulceration score (Difference: -0.70 (StdError:0.24), p=0.006) which was 2.2 
(0.68) for Placebo and 1.5 (1.1) for D-met. While for erythema on a continuous scale (0-
2) the use of D-met was associated with a 0.5 point reduction in peak erythema score 
(Difference: -0.52 (StdError:0.18), p=0.005) which was 1.6 (0.49) for Placebo and 1.1 
(0.82) for D-met.  
 
No significant differences were found for any of the other planned secondary end-points. 
There was no difference in hospitalization rates (3/29 (10%) Placebo vs. 2/29 (7%) D-
met, p=0.64) nor weight loss (4.4 kg (SD:3.0) Placebo vs. 4.2 (SD:3.2) D-met, p=0.8).  
Supportive therapy use was also not different for either opioid analgesics for pain control 
(12/29 (41%) placebo vs. 9/29 (31%) D-met, p=0.62) or the need for total parenteral 
nutrition (4/29 (14%) placebo vs. 1/29 (3%) for D-met, p=0.16).  
 
Per protocol the last day of follow-up was scheduled for 30 days after the completion of 
RT with no difference in attendance at this time (24/29 (83%) placebo vs. 21/29 (72%) D-
met, p=0.35).  Treatment response was assessed by CT scan with 50% of subjects (29/58; 
Placebo=16, D-met=13) having a baseline CT scan, measurable disease on this scan, and 
a follow-up scan at day 30 (Supplemental Table 9). Based upon radiographic review 
blinded to treatment allocation there was no difference in response rates between 
treatments with 62.5% (10/16) response (PR or CR) for placebo and  46.2% response 
(6/13) for D-met (p=0.48).  
 
Unplanned Secondary Analyses 
Peak and Area Under the Time / Mucositis Curve 
As an additional unplanned analysis the time-dependent nature of mucositis was plotted 
for the patient reported RTOG scale in Figure 3B. Mucositis on a scale of 0-4 is plotted 
from the baseline visit (0) through the weekly treatment visits (1-7) and the final follow-
up appointment (8).  The integral of mucositis over time was calculated and reported as 
the Area Under the Curve (AUC) which was higher for Placebo (AUC: 8.3 (95%CI:7.6-
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8.9)) as compared to D-met (AUC: 6.3 (95%CI:5.6-7.0), p=0.036).  This led to a 
protective factor (Placebo/D-met) of 1.3.   
 
For Peak mucositis there was a similar relationship with average peak value of 1.9 
(95%CI:1.5-2.4) for Placebo as compared to 1.3 (95%CI:1.1-1.6) for D-met which was 
statistically different (p=0.005) with a protective factor of 1.5.  Peak mucositis was 
statistically different at weeks 4 and 5 but not at other time-points. A similar relationship 
for time-dependent mucositis and peak mucositis with similar protective factors was seen 
for all 3 scales (Supplemental Table 10).  
 
Missing Data  
One potential confounding factor is that more patients withdrew from treatment with D-
met than with placebo.  For those who dropped out the mucositis score on their last 
assessment was compared between those with Placebo or D-met for any patient who had 
less than 9 mucositis evaluations (Supplemental Table 11).  This revealed that patients 
who missed evaluations on the Placebo arm had higher mucositis scores prior to missing 
data than those on the D-met arm (2.8-3.0 vs. 1.0-1.2, all p-values <0.002).  In addition, 
patients non-evaluable on the Placebo arm had higher peak mucositis scores than Placebo 
patients who completed treatment (2.8-3.0 vs. 2.0-2.0, for all 3-scales, all p-values 
<0.01). In contrast, those who were not evaluable on the D-met arm did not have higher 
peak mucositis scores then the population that was fully evaluable and treated with D-met 
(1.0-1.2 vs. 1.3-1.4, all p-value >0.05).  However, on the D-met arm there was a trend to 
those missing mucositis evaluations having higher rates of grade 1+ nausea (42% vs. 
18%, p=0.09) without a difference in grade 2 or greater nausea; while on the placebo arm 
there was no difference in grade 1 or greater than grade 1 nausea for those who 
completed all mucositis evaluation as compared to those who missed mucositis 
assessments (p>0.5).  Nevertheless, differences in timing of these mucositis evaluations 
in those who dropped out of therapy or did not limit the conclusions to be made based 
upon an uplanned secondary analysis.    
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Radiation Dose and Mucositis 
We also evaluated the impact of RT dose on mucositis for the WHO scale (Supplemental 
Table 12). By univariate regression increasing radiation dose (<20, 20-39, 40-59, 60-70 
Gy) correlated with increasing mucositis (p=0.03) while D-met was protective 
(p=0.0005).  On multivariate regression the use of D-met retained significance (p=0.001) 
while radiation dose was borderline (p=0.064). When analyzed as the likelihood of 
having Grade 3-4 mucositis by logistic regression the use of D-met after adjusting for RT 
dose was associated with a substantial reduction in the rate of Grade 3-4 mucositis (Odds 
Ratio: 0.29 (95%CI:0.09-0.99), p=0.05) while RT dose was not correlated with Grade 3-4 
mucositis (p=0.93). 
 
The Use of 5-Flourouracil and Mucositis 
Some patients also received 5-FU (12 in the Placebo group and 11 in the D-met group, 
Supplemental Table 13) which was outside of recommended protocol therapy.  Logistic 
regression was performed to assess the rate of Grade 3-4 mucositis as a function of 
treatment (Placebo vs. D-met) as well as the use of 5-FU (No vs. Yes) for the WHO scale.  
Overall in this model the use of D-met was protective of Grade 3-4 mucositis (Odds 
Ratio: 0.29 (95%CI:0.09-0.98), p=0.047) while the use of 5-FU did not influence 
mucositis (OR: 0.72 (95%CI:0.21-2.4), p=0.60).  Similarly, when analyzing the complete 
WHO scale for mucositis (0-4) the use of D-met was associated with an approximately 
1.0 point decrease in maximal mucositis score (Difference : 0.87 (StDev: 0.23), 
p=0.0005) while 5-FU use did not influence score (Difference: 0.06 (StDev:0.24), 
p=0.81).  
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This multi-institutional phase 2 trial was undertaken to assess if the efficacy observed in 
the single center Phase I trial of oral D-methionine to prevent OM could be confirmed.  
In planning the trial the control arm was assumed to have a 70% incidence of grade 3-4 
mucositis and that following D-met it would be 10%.  As such a sample size of 40 
evaluable patients was needed.  The observed rate of grade 3-4 mucositis was lower on 
the control arm than anticipated with 14/29 patients (48%) having severe mucositis while 
that in the experimental arm was higher than anticipated with 7/29 (24%) having severe 
mucositis.  As a result this study did not meet its primary end-point of comparing the rate 
of grade 3-4 mucositis between arms based upon the composite scale (p=0.058). Based 
upon other studies it appears that the primary deficiency was that the 70% assumed rate 
of grade 3-4 mucositis on the control arm (as reported for the phase I trial (37)) was 
higher than observed on the control arm of the current study; although the rate we did 
observe is more in line with other published clinical trials. As a result statistical 
significance was not obtained for the primary end-point.  
 
Of note a number of planned and unplanned complementary analyses of mucositis were 
also undertaken with strong support for reduced mucositis in patients treated with D-met.  
This included decreased mucositis when looking at all 4 scales utilized over their full 
range (WHO, RTOG physician, RTOG functional patient, and the composite scale, all 
p<0.003).  In addition, no grade 4 mucositis was noted in any D-met treated patients, 
while 2/29 (7%) of patients had grade 4 mucositis when treated with placebo, and one 
patient died secondary to sepsis on the placebo arm (potentially related to grade 4 
mucositis).  If grade 4 mucositis is addressed separately from grade 3 then all 4 scales 
would also support a protective effect of D-met (all p<0.009).  Another pre-planned 
analysis was the use of the OSSFSA to assess ulceration and erythema separately across 9 
areas of the oral cavity or oropharynx where D-met resulted in lower scores for both of 
these planned evaluations (both p<0.007).  It is well documented that treatment delays for 
SCCHN decrease local control and in a pre-planned analysis the use of D-met was 
associated with an approximate 6 day shorter treatment course than placebo (p=0.05); 
while patients missing treatment on the placebo arm had higher mucositis scores then 
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patients remaining on treatment consistent with treatment breaks for mucositis in the 
placebo arm (all p<0.0016). Finally, unplanned analyses taking into account the time 
depended exposure of mucositis as the AUC as well as the impact of both RT dose and 
the use of 5-FU concurrent with cisplatin and RT all supported a protective effect of D-
met (all p<0.05). 
 
In the preclinical data a stronger correlation was noted between the Cmax of Dmet and 
radiation protection factor (R
2
=0.94) as compared to D-met AUC (R
2
=0.31)(D.A.H. 
unpublished data).  Peak serum concentrations were higher in humans (100 mg/kg po, 
Cmax=192 µg/mL)(37) as compared to rodents (150 mg/kg po, Cmax= 71 µg/mL)(34) 
while given the longer half-life in humans (3.0 hrs vs. 1.0 hrs) the total exposure 
following oral dosing was even higher in man (AUC 793 vs. 211 µg * hr/mL).(34, 37) 
The PF observed here of 1.3-1.5 is lower than that predicted based upon extrapolating 
from a comparable Cmax in rodents which would have been 2.1.(34)  Nevertheless, given 
the much longer half-life in man (and correspondingly much higher AUC) this is still 
most consistent with radiation protection correlating best with peak serum concentration. 
Notably in rodents peak serum concentrations were markedly higher after IV 
administration then after PO which could potentially have implications for further 
development of D-met as a radioprotector. 
 
There were no SAE’s noted with the use of D-met although 4 patients did withdraw from 
the study due to nausea/vomiting (most grade 1-2). This is consistent with previous 
reports of pharmacologic doses of methionine. As a result it is recommended that anti-
emetics that are active in the setting of mildly emesis inducing drugs be utilized 
prophylactically if D-met is going to be administered as outlined herein. 
 
Oral mucositis continues to be a significant burden for patients treated for SCCHN with 
combined chemoRT.  The current study was undertaken in India where consumption of 
betel nut leads to a high rate of squamous cell cancers involving the oral cavity and 
oropharynx.  However, in western countries alcohol and tobacco related SCCHN were 
traditionally more prevalent while more recently there has been a significant increase in 
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SCCHN related to human papilloma virus infection.  Nevertheless, the combination of 
radiotherapy and chemotherapy is still associated with oral or pharyngeal mucositis in a 
high proportion of patients regardless of patient heritage or the causative agent for their 
SCCHN (2). In addition, the treatment utilized here with CT planned 2- or 3D conformal 
therapy also does not reflect current treatment standards; however, newer technologies 
such as parotid sparing intensity modulated RT (IMRT) have not reduced mucositis, 
perhaps due to spreading dose more to mucosal surfaces with IMRT.  The only phase III 
trial comparing 3D-conformal RT to parotid sparing IMRT reported a numerically higher 
but not significantly different rate of grade 3-4 mucositis in those getting IMRT as 
compared to 3D-treatments (60% IMRT vs. 44% 3D, p>0.05)(39). Similarly in a 
randomized trial the use of every 3-week cisplatin (100 mg/m
2
) also correlated with a 
higher (albeit not statistically different) rate of oral mucositis when compared to weekly 
cisplatin (30 mg/m
2
)(53% vs. 40%, p>0.05)(40). In this context the rate of grade 3-4 
mucositis observed here using conventional RT and weekly cisplatin (48%) is consistent 
with these previous reports while that with the addition of D-met (24%) is lower. As a 
result the protective effect of D-met potentially identified herein likely is still applicable 
even with different demographic and treatment related characteristics. 
 
A number of other agents have been reported recently as to their ability to mitigate oral 
mucositis.  Most prominently is topical honey where 4 small phase 3 trials (all performed 
ex-US) appeared to show significantly reduced mucositis as compared to placebo or best 
standard of care with the most common regimen being topical honey administered before 
and two times after RT for up to 6 hours. Given the antibacterial and anti-microbial 
properties reported for honey it is felt that this may be its mechanism of action. A recent 
large phase 2 trial performed by the RTOG in patients receiving thoracic RT, however, 
did not note a benefit of Manuka Honey using either liquid or lozenge formulation as 
compared to best standard of care in reducing esophagitis(41). Benzydamine (a locally 
acting topical non-steroidal anti-inflammatory) was also demonstrated to decrease OM 
when compared to saline mouth wash daily during RT with the greatest effect in reducing 
oral pain(42).  Caphasol, which is marketed to lubricate the mouth for xerostomia, did not 
result in any decrease in mucositis when provided during RT(43).  Finally, in a single 
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dose study the use of Doxepin (a tri-cyclic anti-depressant) or “Magic Mouth Wash” 
(lidocaine containing rinse) each compared to placebo noted decrease oral pain in the first 
60 minutes with either experimental agent while those receiving doxepin had increased 
fatigue compared to placebo(44). 
 
Taken together the results reported here are suggestive of a protective effect of D-
methionine in preventing OM.  Although the study did not achieve its primary end-point 
the remainder of the data are robust and supportive of an effect. Further studies of D-met 
powered to assess tumor response as well as mucosal protection are warranted.   
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Figure 1 : Consort Diagram 
 
Figure 2: Maximum Mucositis score (and standard error) observed for the World Health 
Organization (WHO) (A), Radiation Therapy Oncology Group (RTOG) Physician (B), 
RTOG Functional Patient (C), or Composite Scale (D) 
 
 
Figure 3: Oral mucositis by maximum grade using the Objective Scoring System for Site 
Assessment (mean number of observations with standard error) by treatment arm for 
placebo or D-methionine (D-met) treatment.  (A). Time dependent analysis of mucositis 
using the RTOG Functional Patient Rating (mean score with standard error) along with 
calculated peak and area under the curve (AUC) (B) 
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(number = 29) 
Placebo 
(number = 29) 
p-value 
Age: (years) 
     Mean (SD) 
     Median (Min, Max) 
 
50.2 (11.4) 
52 (23, 64) 
 
47.7 (9.4) 






     Male 






















     Mean (SD) 
     Median (Min, Max) 
 
56.3 (10.4) 
56 (35, 80) 
 
53.3 (11.0) 





Body Mass Index: (kg/m
2
) 
     Mean (SD) 
     Median (Min, Max) 
 
21.6 (3.5) 
22.0 (15.1, 30) 
 
20.9 (4.7) 





Karnofsky Performance Status: 
     Mean (SD) 
     Median (Min, Max) 
     70 [Number(%)] 
     80 [Number(%)] 
     90 [Number(%)] 
 
88.2 (4.7) 















    
Time from Diagnosis to Randomization  












     Squamous Cell 











Site of Primary Tumor [Number(%)]
a
 
     Oral Cavity 
     Oropharynx 
     Hypopharyngeal 
     Salivary Gland 
     Nasopharyngeal 





















       I 
       II 
      III 
      IV 
      Stage III/IV 



























Sites of Metastases [Number(%)]
a
  
  Any 
     Lymph nodes, neck 
         Cervical 
         Submandibular 

















Table 1 : Demographic and Clinical Characteristics 
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Radiotherapy:    
Number of Fractions Received per Patient 
     Mean (SD) 
     Median (Min,Max) 
 
26.6 (9.0) 
30 (1, 35) 
 
29.7 (5.7) 





Total Gy Administered per Patient  
     Mean (SD) 
     Median(Min, Max) 
 
52.2 (18.6) 
60 (1.8, 70) 
 
57.8 (12.1) 





Time to Complete RT per Patient [Days] 
     Mean (SD) 
     Median (Min, Max) 
 
39.6 (14.6) 
42 (1, 65) 
 
47.1 (12.2) 





Number (%) Treatment Device 
      Cobalt 











Cisplatin:    
Number (%) of Patients Receiving >1  









Number of Cisplatin Doses per Patient  
     Mean (SD) 
     Median (Min, Max) 
 
3.2 (1.9) 
4 (0, 6) 
 
3.2 (1.8) 





Study Drug:    
Number of Doses Administered per Patient     
     Mean (SD) 
     Median (Min, Max) 
 
52.7 (18.3) 
60 (2, 69) 
 
59.5 (11.5) 





Number of Days Dosed per Patient 
     Mean (SD) 
     Median (Min, Max) 
 
26.7 (9.1) 
30 (1, 35) 
 
29.7 (5.8) 

















Table 2:  Summary of Study Treatment 
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a Totals for each body system count each patient once, using the highest grade of AE reported within that body system.   
b Totals for individual AEs count each patient once.  If multiple occurrences of the same AE were reported, the patient was counted once under the 
highest intensity of that event. 
cOne patient in the placebo treatment group developed Grade 4 AEs of anemia, hypotension, and dyspnea resulting in his death (Grade 5) 
 
Table 3.  Summary of Most Frequently Reported (>10%) All-Cause Adverse Events by Body Systema,  Maximum Intensityb, and Treatment Group  
 D-methionine  Placebo 
BODY SYSTEM a (Number = 29)  (Number = 29) 
      
 
















TOTAL PATIENTS 29 (100) 1 18 10 0  29 (100) 2 15 11 1 (Gr. 5c) 
            
DIGESTIVE / GASTROINTESTINAL 29 (100) 5 16 8 0  28 (96.6) 1 15 12 0 
  Vomiting 16 (55.2) 8 7 1 0  13 (44.8) 3 9 1 0 
  Nausea 16 (55.2) 11 4 1 0  5 (17.2) 2 3 0 0 
  Pain in oral cavity 16 (55.2) 3 9 4 0  25 (86.2) 2 15 8 0 
  Constipation 12 (41.4) 9 3 0 0  6 (20.7) 5 1 0 0 
  Anorexia 6 (20.7) 1 2 3 0  8 (27.6) 0 3 5 0 
  Dysphagia 5 (17.2) 2 2 1 0  6 (20.7) 2 2 2 0 
  Diarrhea 4 (13.8) 4 0 0 0  3 (10.4) 2 1 0 0 
  Dyspepsia / Heartburn 3 (10.3) 1 2 0 0  1 (3.4) 1 0 0 0 
  Xerostomia 1 (3.4) 1 0 0 0  3 (10.4) 2 0 1 0 
  Infection in Oral Cavity 1 (3.4) 0 1 0 0  3 (10.4) 0 3   0       0 
            
CONSTITUTIONAL SYMPTOMS 22 (75.9) 2 18 2 0  18 (62.1) 6 11 1 0 
  Odor (Body, Breath or Urine) 15 (51.7) 3 11 1 0  2 (6.9) 1 1 0 0 
  Fatigue 10 (34.5) 2 7 1 0  11 (37.9) 2 8 1 0 
  Fever 5 (17.2) 2 3 0 0  7 (24.1) 5 2 0 0 
  Insomnia 4 (13.8) 1 3 0 0  5 (17.2) 2 3 0 0 
            
MUSCULOSKELETAL SYSTEM 12 (41.4) 4 7 1 0  9 (31.0) 4 4 1 0 
  Pain in Jaw 7 (24.1) 3 3 1 0  6 (20.7) 1 4 1       0 
  Pain in Ear 4 (13.8) 1 3 0 0  2 (6.9) 1 1 0 0 
 
PULMONARY 10(34.5) 6 4 0 0  11 (37.9) 5 4 1 1 
 Cough 8 (27.6) 5 3 0 0  9 (31.0) 5 4 0 0 
 Pain, Sore Throat 3 (10.3) 1 2 0 0  1 (3.4) 0 1 0 0 
            
DERMATOLOGIC CONDITIONS 9 (31.0) 6 3 0 0  9 (31.0) 7 2 0 0 
 Rash 8 (27.6) 6  2 0 0  8 (27.6) 6 2 0 0 
            
BODY AS A WHOLE 4 (13.8) 0 2 2 0  3 (10.3) 1 2 0 0 
  Infection 3 (10.3) 6 2 0 0  1 (3.4) 0 1 0 0 
            
BLOOD / BONE MARROW 4 (13.8) 0 2 2 0  3 (10.3) 1 1 0 0 
 Leukopenia 1 (3.4) 0 0 1 0  3 (10.3) 1 1 1 0 


































Page 30 of 43







































































t   
 
 
Figure 1  
 
254x190mm (96 x 96 DPI)  
Page 31 of 43
John Wiley & Sons, Inc.
Head & Neck









t   
 
 
Figure 2  
 
254x190mm (96 x 96 DPI)  
Page 32 of 43
John Wiley & Sons, Inc.
Head & Neck









t   
 
 
Figure 3  
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tInclusion Criteria: • Histological confirmation of head and neck cancer, first occurrence; • Medically suited to receive primary treatment with radiation and cisplatin; • 18-65 years; • Radiation area should include a minimum of 50% of the oral pharynx, oral cavity, or both; 
• Negative serum pregnancy test in females of child-bearing potential; 
• KPS >60; 




• Breast feeding; 
• T1 and T2 glottic tumors; 
• Prior radiation to the head and neck region or prior chemotherapy of any type; 
• History of allergic or idiosyncratic reaction to methionine, amino acid mixtures, strength formulations, egg white, other proteins, 
food additives; 
• Simultaneous enrollment in other clinical studies; 
• Other immunocompromised states,  
• Current oral mucosal lesions other than from direct involvement of the underlying head and neck cancer; 
• Cryotherapy to the face, head and neck region; 
• Current use of any of the following oral care preparations: amifostine, chlorhexidine, sucralfate, benzydamine. 
 
Supplemental Table 1 : Inclusion and Exclusion Criteria 
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Ulceration Scoring:     Erythema Scoring: 
0 = No Lesion    0 = None 
1 = <1 cm
2
    1 = Mild 
2 = 1-3 cm
2
     2= Severe 
3 = >3 cm
2    
 
 
Supplemental Table 4.  Objective Scoring System for Site Assessment (OSSFSA) 
Location Ulceration/Pseudomembrane Erythema 
Any Site 0 1 2 3 0 1 2 
Upper Lip 0 1 2 3 0 1 2 
Lower Lip 0 1 2 3 0 1 2 
Right Cheek 0 1 2 3 0 1 2 
Left Cheek 0 1 2 3 0 1 2 
Right Ventral and Lateral 
Tongue 
0 1 2 3 0 1 2 
Left Ventral and Lateral 
Tongue 
0 1 2 3 0 1 2 
Floor of Mouth 0 1 2 3 0 1 2 
Soft Palate / Fauces 0 1 2 3 0 1 2 
Hard Palate 0 1 2 3 0 1 2 
Supplemental Table 2.  World Health Organization Grading Scale for Mucositis 
(WHO) 
Grade Description 
0 No mucositis 
1 Painless ulcer, erythema or mild soreness 
2 Painful erythema, edema, ulcer, but can eat 
3 Painful erythema, edema, ulcer, but cannot eat 
4 Required parenteral or enteral support 
Supplemental Table 3.  Radiation Therapy Oncology Group Oral Mucositis 
Grading System (RTOG) 
Score Gross Physician Rating Functional Patient Rating 
0 None None 
1 Erythematous sores Mild soreness, mild dysphasia.  Solid 
diet possible. 
2 Patchy mucositis (<1/2 
mucosa) 
Moderate pain, moderate dysphasia.  
Soft diet or liquid diet possible. 
3 Confluent fibrinous 
mucositis (>1/2 mucosa) 
Severe pain, severe dysphasia.  Liquids 
only. 
4 Hemorrhage and necrosis Requires parenteral or enteral support. 
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0 1 2 3 4  0 1 2 3 4 














































            
Platelet Count 
Nadir 
24 (100) 0 0 0 0  26 (92.9) 1 (3.6) 1 (3.6) 0 0 
            
Hemoglobin 
Nadir 
8 (33.3) 12 (50.0) 4 (16.7) 0 0  9 (32.1) 14 (50.0) 5 (17.9) 0 0 
 
 
           
a
 The worst post-baseline test result was graded according to the CTCAE,v3.0 
b
 The total number of patients reported in a treatment group reflects the number of patients who had >1 post-baseline test 







 The worst post-baseline test result was graded according to the CTCAE,v3.0 
b
 The total number of patients reported in a treatment group reflects the number of patients who had >1 post-baseline test 




Supplemental Table 6.  Summary of Patients with Abnormal Chemistry Parameters, by Maximum Grade
a
 







































            
Total Bilirubin 22 (91.7) 1 (4.2) 1 (4.2) 0 0  27 (96.4) 1 (3.6) 0 0 0 
            
AST 19 (79.2) 5 (20.1) 0 0 0  23 (82.1) 4 (14.3) 0 1 (3.6) 0 
            
ALT 21 (87.5) 3 (12.5) 0 0 0  25 (89.3) 2 (7.2) 1 (3.6) 0 0 
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 Total Patients:  Patients were counted once regardless of how many SAEs were reported in that patient. 
Supplemental Table 7.  Summary of All Serious Adverse Events by Body System and Treatment Group 
 D-methionine  Placebo 
BODY SYSTEM (Number = 29)  (Number = 29) 












Grade 2 Grade 3 Grade 4 Grade 5 
           
TOTAL PATIENTS
a
 (%) 3  (10.3) 1 (3.4) 2 (6.9) 0  4 (13.8) 0 3 (10.3) 0 1 (3.4) 
           
TOTAL SAEs 11 2 9 0  13 4 6 2 1 
           
HEMATOLOGIC           
   Neutropenia/Leukopenia 2 0 2 0  2 1 1 0 0 
   Hemorrhage/ 





















   Anemia 2 1 1 0  1 0 0 1 0 
           
DIGESTIVE           
   Dysphagia 1 0 1 0  2 0 2 0 0 
   Anorexia 1 0 1 0  1 0 1 0 0 
   Pain in Oral Cavity 1 0 1 0  3 1 2 0 0 
           
OTHER BODY SYSTEMS           
   Fatigue 1 0 1 0  0 0 0 0 0 
   Edema 1 1 0 0  0 0 0 0 0 
   Infection 1 0 1 0  1 1 0 0 0 
   Dyspnea 0 0 0 0  1 0 0 1 0 
   Hypotension 0       0       0       0  1       0       0      0      1 
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=Fisher’s exact test 
 
Supplemental Table 8.  Summary of Significant Protocol Deviations  




Number = 29 
Placebo 
Number = 29 
p-value 
Pregnancy test not done during Baseline 2 (6.9) 2 (6.9)  1.0
a
 
CT scans not obtained: 
     at Baseline 
























Patient did not receive any doses of cisplatin  4 (13.8) 4 (13.8) 1.0
a
 
Patient received carboplatin instead of cisplatin 1 (3.4) 1 (3.4) 1.0
a
 
Missed one or more doses of Study Medication 









Patient received doses of 5-fluorouracil in 
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Supplemental Table 9.  Objective Response Rate via RECIST Criteria Based on 
a Subset of 29 Patients with a Baseline CT Scan, a Follow-Up CT Scan, and 




Number = 13 
Placebo 
Number = 16 
Complete Response 2 (15.4) 1 (6.2) 
Partial Response 4 (30.8) 9 (56.2) 
CR + PR 6 (46.2) 10 (62.5) 
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Placebo 8.3 7.6 0.035 
all 
1.3 / 1.3 
2.0 1.9 0.0056 
all 
1.5 / 1.4 
D-met 6.3 5.6 0.036 
full 





Placebo 8.9 8.3 0.012 
all 
1.4 / 1.4 
2.0 2.0 0.0014 
all 
1.4 / 1.4 
D-met 6.7 5.9 0.034 
full 






Placebo 8.5 7.9 0.017 
all 
1.4 / 1.4 
2.0 1.9 0.002 
all 
1.5 / 1.4 
D-met 6.3 5.6 0.038 
full 
1.3 1.3 0.002 
full 
Supplemental Table 10: Peak and Time Dependent Analysis of Mucositis By Treatment Arm as Well as 
Protective Factors 
 
The total time dependent response of mucositis to chemoradiotherapy with or without D-
met was evaluated (as seen for Figure 3A which was for the Functional Patient Scale from 
the RTOG scale) using all 3 scales. This score was calculated as the integral of mucositis 
over time and expressed as the Area Under The Curve (AUC). Given the secondary nature 
of the analysis it was performed in two ways.   
 
First, there were nine time points at which mucosal evaluation was performed (baseline, 
weekly during RT for up to 7 weeks, and at 30 days post RT).  For the time dependent 
analysis reported here a patient was included in the analysis only if mucosal evaluation was 
performed at a minimum 6 of 9 data points (Placebo: 24/29 patients and D-met: 20/29 





.   
 
Second, analysis was also limited to those in whom all 9 data points were available which 




 (Placebo: 23/29 patients and D-met: 18/29 patients, Chi-
square: p=0.5).  
 
The protective factor was calculated as the value for AUC or Peak mucositis score with 
Placebo divided by the score with D-met where a value >1.0 would indicate lower 
mucositis with D-met. 
 
Overall there was a higher AUC reflecting higher exposure to mucositis in the placebo 
arms on all three scales as compared to the D-met arm with protective factors of 1.3-1.4.  
Similarly, there were higher peak mucositis scores across all analyses for those treated with 
Placebo than those treated with D-met with protective factors of 1.4-1.5. No significant 
differences were noted between any of the scales. Comparisons for average AUC and 
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Placebo 3.0 (0.63) 2.8 (0.41) 2.8 (0.75) 
D-methionine 1.1 (1.22) 1.2 (1.07) 1.0 (1.12) 
t-test 0.0014 0.0013 0.0015 
Supplemental Table 11: Mucositis score on last evaluable day for those with <9 scores 
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Supplemental Table 12.  Summary of Maximum WHO Oral Mucositis Scores  





D-met (N = 29) Grade 
3-4 
D-met 



























<20 3 0 0 0 0 0% 
(0/3) 




20-39 1 0 2 0 0 0% 
(0/3) 




40-59 0 2 3 1 0 17% 
(1/6) 




60-70 3 1 9 4 0 24% 
(4/17) 




Overall 7 3 14 5 0 17% 
(5/29) 
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t  Supplemental Table 13: Grade 3-4 Mucositis as a Function of 5FU Use and D-met 
 Percentage with Grade 3-4 Mucositis Based on WHO Scale 
 No 5FU 5FU 
Placebo 47.1% (8/17) 33.3% (4/12) 
D-meth onine 16.7% (3/18) 18.2% (2/11) 
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